Standout Papers
- K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer (2008)
- Cetuximab for the Treatment of Colorectal Cancer (2007)
- Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial (2009)
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab (2010)
Immediate Impact
2 by Nobel laureates 13 from Science/Nature 100 standout
Citing Papers
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial
2024 Standout
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
2023 Standout
Works of Chris J. O’Callaghan being referenced
Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer
2022
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17
2015
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Chris J. O’Callaghan | 6112 | 2829 | 1877 | 106 | 8.8k | |
| Paul Ruff | 6251 | 2538 | 1732 | 153 | 8.6k | |
| Patrick J. Flynn | 6762 | 2563 | 2172 | 144 | 10.9k | |
| Rosalba Miceli | 4358 | 5207 | 1394 | 248 | 10.4k | |
| David Khayat | 5160 | 2557 | 1183 | 103 | 8.2k | |
| Tamas Hickish | 9922 | 4218 | 2234 | 142 | 13.2k | |
| Irene Floriani | 3260 | 2261 | 1209 | 157 | 8.1k | |
| Roscoe F. Morton | 4512 | 1851 | 1378 | 97 | 7.6k | |
| Andrea Bonetti | 6079 | 1874 | 1171 | 152 | 7.9k | |
| Kristine Broglio | 7038 | 2561 | 2238 | 145 | 12.0k | |
| James E. Krook | 10087 | 5725 | 1371 | 135 | 14.4k |
All Works
Login with ORCID to disown or claim papers
Loading papers...